IDEXX Laboratories, Inc. $IDXX Shares Sold by Stance Capital LLC

Stance Capital LLC lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 94.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 400 shares of the company’s stock after selling 6,587 shares during the period. Stance Capital LLC’s holdings in IDEXX Laboratories were worth $271,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of IDXX. Beacon Investment Advisory Services Inc. boosted its stake in IDEXX Laboratories by 11.9% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after buying an additional 6,710 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of IDEXX Laboratories by 114.1% during the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after purchasing an additional 8,845 shares during the period. Procyon Advisors LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth $1,966,000. Diversified Trust Co. increased its position in shares of IDEXX Laboratories by 223.5% during the 4th quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after purchasing an additional 2,901 shares during the last quarter. Finally, Mirabella Financial Services LLP increased its position in shares of IDEXX Laboratories by 156.2% during the 3rd quarter. Mirabella Financial Services LLP now owns 4,401 shares of the company’s stock worth $2,806,000 after purchasing an additional 2,683 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on IDXX. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. UBS Group decreased their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Finally, Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Price Performance

IDXX stock opened at $562.09 on Monday. The business’s fifty day moving average price is $561.66 and its 200 day moving average price is $620.14. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $44.34 billion, a PE ratio of 41.39, a P/E/G ratio of 3.07 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period last year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.